M
CRL icon

Mirova’s Charles River Laboratories CRL Stock Holding History

Mirova’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-115
Closed -$24.2K – 132
2023
Q2 		$24.2K Sell
115
-198
-63% -$39.4K ﹤0.01% 161
2023
Q1 		$63.2K Buy
+313
New +$70.9K 0.01% 162

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Mirova's CRL Position: Q3 2023 in Review

Mirova sold out of Charles River Laboratories (CRL) in Q3 2023, closing a stake of 115 shares — an estimated $24.2K sold.

Mirova first reported a position in CRL in Q1 2023 and held it in 2 quarters. The position peaked at $63.2K in Q1 2023. 621 funds tracked by Wall St. Rank hold CRL as of Q3 2023.

  • Mirova reported no remaining Charles River Laboratories position as of Q3 2023 after selling out during the quarter.
  • Mirova sold 115 Charles River Laboratories shares in Q3 2023, an estimated $24.2K.
  • Mirova first reported a position in Charles River Laboratories in Q1 2023 and held it in 2 quarters.
  • Mirova's Charles River Laboratories position peaked at $63.2K in Q1 2023.
  • 621 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2023.

Based on Mirova's 13F filing for Q3 2023, filed 14 Nov 2023.